Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Taliglucerase alfa in Pediatric Gaucher Disease
2011-003676-37Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Sep 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of taliglucerase alfa in Gaucher disease (GD), sponsored by Protalix BioTherapeutics. Primary endpoint: Efficacy variables. Started Sep 2011; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on 2011-003676-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003676-37.